Abstract
Hyperphosphataemia is a usual accompaniment of end stage renal disease and dialysis, in the absence of dietary phosphate restriction or supplemental phosphate binders. It is associated with renal osteodystrophy, metastatic calcification and increased mortality and morbidity. Despite dietary restriction and dialysis, most patients will require a phosphate-binding agent to treat this condition. However, phosphate control has not significantly improved over the last two decades, mainly because of the lack of an ideal oral phosphate-binding agent. Aluminium- and calcium-based agents are associated with major side effects, despite their undoubted efficacy. Although sevelamer hydrochloride represents a step forward in the management of hyperphosphataemia, it is not an ideal phosphate binder due to its cost and tablet burden. Lanthanum carbonate is the most recent non-calcium, non-aluminium, phosphate-binding agent. It is effective and well-tolerated, and no negative effects on bone histology have been observed. © 2005 Ashley Publications Ltd.
Original language | English |
---|---|
Pages (from-to) | 319-328 |
Number of pages | 9 |
Journal | Expert opinion on pharmacotherapy |
Volume | 6 |
Issue number | 2 |
DOIs | |
Publication status | Published - Feb 2005 |
Keywords
- Chronic renal failure
- End stage renal disease
- Hyperphosphataemia
- Renal osteodystrophy